PURPOSE
The purpose of this study is to assess the safety and effectiveness of adding the drug evexomostat (SDX-7320) to standard eribulin chemotherapy in people with triple-negative breast cancer (TNBC) that has come back or spread despite treatment.  In addition, the participants in this study have metabolic disorders such as high blood sugar and/or obesity.

TNBC includes breast cancers do not contain receptors for estrogen or progesterone and do not have the HER2 protein, so they cannot be treated with medications that target those proteins.

Metabolic disorders, such as high blood sugar and/or obesity, can accelerate the growth of breast cancers and possibly cause resistance to standard cancer treatments. Evexomostat has been shown to slow tumor growth, improve metabolic disorders, and was safe when given by itself in earlier phase 1 trials. This study will determine whether there is a benefit to adding evexomostat to standard chemotherapy.

Evexomostat works by blocking an enzyme (MetAP2) that helps cancer cells multiply and also plays a role in improving metabolic disorders. Participants will receive one of these treatments:

• Evexomostat plus eribulin
• Eribulin plus a placebo (inactive drug)

Evexomostat is given as a subcutaneous (under the skin) injection once every 2 weeks and eribulin is given intravenously (by vein).